Proprotein Convertase Subtilisin/kexin Type 6 (Pcsk6) Plays A Role In Angiogenesis Regulation

被引：0
作者：
Chemaly, Melody
Dong, Xinran
Suur, Bianca E.
Jin, Hong
Malarstig, Anders
Matic, Ljubica
机构：
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2022年 / 42卷
关键词：
Atherosclerosis; Plaque angiogenesis;
D O I：
10.1161/atvb.42.suppl_1.105
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
105
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Advancing Research on Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Scientometric Analysis
    Matin, Abdul
    Chaudhry, Gul-e-Saba
    Azra, Mohamad Nor
    Gazli, Mohamad
    Sung, Yeong Yik
    Muhammad, Tengku Sifzizul TENGku
    MALAYSIAN JOURNAL OF MEDICAL SCIENCES, 2024, 31 (04): : 14 - 34
  • [22] Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
    Denis, Maxime
    Marcinkiewicz, Jadwiga
    Zaid, Ahmed
    Gauthier, Dany
    Poirier, Steve
    Lazure, Claude
    Seidah, Nabil G.
    Prat, Annik
    CIRCULATION, 2012, 125 (07) : 894 - U173
  • [23] Elevation of serum proprotein convertase subtilisin/kexin type 9 (PCSK9) concentrations and its possible atherogenic role in patients with systemic lupus erythematosus
    Fang, Chenglong
    Luo, Tingting
    Lin, Ling
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (23)
  • [24] Proprotein convertase subtilisin kexin type 9 and main artery atherosclerosis in patients with arterial hypertension
    Vukolova, Yulia
    Gubareva, Irina
    Galati, Giuseppe
    Germanova, Olga
    MINERVA CARDIOLOGY AND ANGIOLOGY, 2023, 71 (02) : 129 - 134
  • [25] Serum proprotein convertase subtilisin/Kexin type 9 and vascular disease in type 2 diabetic patients
    Armentaro, Giuseppe
    Carbone, Federico
    Cassano, Velia
    Liberale, Luca
    Minetti, Silvia
    Bertolotto, Maria Bianca
    Mannino, Gaia
    Fiorentino, Teresa V.
    Perticone, Maria
    Succurro, Elena
    Sesti, Giorgio
    Montecucco, Fabrizio
    Andreozzi, Francesco
    Sciacqua, Angela
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2023, 53 (03)
  • [26] Predictors of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitor Prescriptions for Secondary Prevention of Clinical Atherosclerotic Cardiovascular Disease
    Blumenthal, Daniel M.
    Maddox, Thomas M.
    Aragam, Krishna
    Sacks, Chana A.
    Virani, Salim S.
    Wasfy, Jason H.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2021, 14 (09): : E007237
  • [27] Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease
    Aydogan Baykara, Rabia
    Yilmaz, Pinar Diydem
    Goktepe, Mevlut Hakan
    Kadiyoran, Cengiz
    Ogul, Mustafa
    Kucuk, Adem
    Cumhur Cure, Medine
    Cure, Erkan
    CLINICAL AND EXPERIMENTAL HYPERTENSION, 2022, 44 (05) : 480 - 486
  • [28] Proprotein convertase subtilisin-kexin type 9 as a biomarker for the severity of coronary artery disease
    Li, Sha
    Zhang, Yan
    Xu, Rui-Xia
    Guo, Yuan-Lin
    Zhu, Cheng-Gang
    Wu, Na-Qiong
    Qing, Ping
    Liu, Geng
    Dong, Qian
    Li, Jian-Jun
    ANNALS OF MEDICINE, 2015, 47 (05) : 386 - 393
  • [29] Vaccine strategies for lowering LDL by immunization against proprotein convertase subtilisin/kexin type 9
    Chackerian, Bryce
    Remaley, Alan
    CURRENT OPINION IN LIPIDOLOGY, 2016, 27 (04) : 345 - 350
  • [30] Hypercholesterolemia,low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
    Hong-mei Gu
    Da-wei Zhang
    The Journal of Biomedical Research, 2015, 29 (05) : 356 - 361
12345